What does HER2 status mean for Triple-Negative Breast Cancer treatment

HER2 Status and Triple-Negative Breast Cancer: What You Need to Know

This is an important question, and the answer involves some nuance that's worth understanding clearly.

What "Triple-Negative" Actually Means

Triple-negative breast cancer (TNBC) is defined by the absence of three key receptors:

• ER-negative (estrogen receptor not present)
• PR-negative (progesterone receptor not present)
• HER2-negative (HER2 protein not significantly present)

By definition, if your cancer is diagnosed as triple-negative, your HER2 status is negative. This means standard HER2-targeted therapies like trastuzumab (Herceptin) are typically not the primary treatment approach.

However—There's Important Emerging Context

According to the webinar "Clinical Guidance from Proteomics," the traditional way we categorize HER2 is becoming more complex. Here's what's changing:

The "HER2 Low" Discovery: Researchers examining breast cancer samples found that even cancers classified as HER2-negative (IHC 0, 1+, or 2+) can have varying levels of HER2 protein expression. Some of these "HER2-low" cancers actually express measurable amounts of HER2—just not the high levels seen in HER2-positive cancers.

This matters because a newer drug called trastuzumab deruxtecan (Enhertu) was specifically designed to work in HER2-low patients. In clinical trials, HER2-low breast cancer patients treated with Enhertu showed an overall survival of 24 months compared to 17 months for those receiving chemotherapy alone.

What This Means for Your Treatment

For standard triple-negative breast cancer:

• Chemotherapy remains the backbone of treatment
• Immunotherapy options (like checkpoint inhibitors) are increasingly important
• Your oncologist may consider clinical trials

The emerging opportunity: If your pathology report shows you're triple-negative, your doctor might consider:

1. Measuring your actual HER2 protein levels (not just the IHC category)
2. Discussing whether Enhertu could be an option if you have detectable HER2 expression
3. Exploring clinical trials that combine newer approaches

Questions to Ask Your Oncologist

1. "Has my HER2 status been measured at the protein level, or just by the standard IHC scoring?" This distinction matters now.

2. "If I'm HER2-low, would Enhertu (trastuzumab deruxtecan) be appropriate for my situation?"

3. "Are there clinical trials available that might be relevant to my specific HER2 expression level?"

4. "What immunotherapy options are being considered as part of my treatment plan?"

5. "How will you monitor my response to treatment, and what biomarkers will you track?"

The Bottom Line

While triple-negative breast cancer by definition has low/absent HER2, the emerging science shows that HER2 expression exists on a spectrum. Modern testing can now detect these lower levels, which may open up new treatment possibilities like Enhertu that weren't available before.

According to NCCN Guidelines and the clinical evidence presented in these webinars, your oncologist should be evaluating not just whether you're HER2-positive or negative, but how much HER2 protein your specific tumor expresses—because that level increasingly determines which targeted therapies might help.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.